Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing
Reexamination Certificate
2007-03-06
2007-03-06
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
C424S045000, C424S046000, C424S489000, C514S177000
Reexamination Certificate
active
10628965
ABSTRACT:
The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.
REFERENCES:
patent: 6182655 (2001-02-01), Keller et al.
patent: 6645466 (2003-11-01), Keller et al.
patent: 0 416 950 (1990-09-01), None
patent: 0 416 951 (1990-09-01), None
patent: WO 93/11773 (1993-06-01), None
patent: WO 9915182 (1999-04-01), None
patent: WO 00/53157 (2000-09-01), None
Adjei and Gupta, InInhalation Delivery of Therapeutic Peptides and Proteins, Adjei and Gupta eds., Marcel Dekker, Inc., New York, 1997, Chapter 22, pp. 625-637.
Bolhuis and Lerk (1981).J. Pharm. Pharmacol. 33: 790.
Braun et al. (1996).Int. J. Pharm. 135: 53-62.
Byron, InRespiratory Drug Delivery, Byron ed., CFC Press, Inc., Boca Raton, 1990, pp. 169-170.
Chowhan and Chi (1986).J. Pharm. Sci. 75: 534-541.
Ganderton (1969).J. Pharm. Pharmac. 21: 9S-18S.
Geuns et al. (1997).European J. Pharm. and Biopharm. 44: 187-194.
Handbook of Pharmaceutical Excipients, 2nded., 1994, pp. 280-282.
Hickey et al. (1994).Pharma. Tech.pp. 58, 60, 62-64, and 82.
Mahmoud and El-Shaboury (1985).Acta. Pharm. Fenn. 94: 125-131.
Martindale: The Extra Pharmacopeia, 28thed., Reynolds ed., The Pharmaceutical Press, London, 1993, Abstract 6022-f.
Meakin et al. (1995).Int. J. Pharm. 119: 103-108.
MIMS (Monthly Index of Medical Specialties), Nov. 1996, pp. 244-245.
MIMS (Monthly Index of Medical Specialties), Oct. 1998, pp. 271-273.
Murthy and Samyn (1977).J. Phar. Sci. 66: 1215-1219.
Note for Guidance on Development Pharmaceutics, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, CPMP/QWP/155/96, Jan. 28, 1998.
Note for Guidance on Dry Powder Inhalers, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, CPMP/QWP/158/96, Jun. 24, 1998.
Peart et al. (1997).Pharm. Res. 14: S-142-S-143, Abstract No. 1405.
Pharmaceutics: The Science of Dosage Form Design, ed. Michael E. Aulton, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1988, p. 56.
Price et al. (2002).Int. J. Pharm. 246: 47-59.
Remmington's Pharmaceutical Sciences, 18thed., 1990, Chapter 31, pp. 589-593, and 602; Chapter 76, pp. 1451-1452; and Chapter 89, pp. 1633, 1636, and 1637.
Respiratory Drug Delivery II, paper presented by John N. Staniforth at a meeting in Keystone, CO, Mar. 26-30, 1990.
Statutory Declaration from Professor David Ganderton, Dec. 15, 2003, In the Matter of an opposition by Vectura Limited to EP 1 131 059 in the name of Jago Research AG.
van Kamp et al. (1986).Pharm. Acta. Helv. 61: 22-29.
Young et al. (2003).J. Pharm. Sci. 92: 815-822.
Zeng et al., InParticulate Interactions in Dry Powder Formulations for Inhalation, Taylor and Francis, Inc., New York, 2001, Sections 1.6.7 (pp. 23-24) and 5.5.6. (pp. 163-165).
Keller Manfred
Müller-Walz Rudi
Biswas, Esq. Naomi S.
Elrifi, Esq. Ivor R.
Haghighatian Mina
Jagotec AG
Mintz Levin
LandOfFree
Dry powder for inhalation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dry powder for inhalation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dry powder for inhalation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797484